Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23912877 | 0.84 | NPC1 (0.41) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL31069783 | 0.84 | NPC1 (0.66) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL918871 | 0.84 | NPC1 (0.66) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL30106823 | 0.84 | NPC1 (0.66) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL14148163 | 0.84 | NPC1 (0.66) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL245302 | 0.84 | NPC1 (0.66) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL245303 | 0.84 | NPC1 (0.66) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL21351775 | 0.84 | NPC1 (0.66) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL12786269 | 0.83 | NPC1 (0.64) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL7183038 | 0.81 | NPC1 (0.62) | NPC1MAPTRAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022235-B2 | Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use | CELLECTAR, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-7893286-B2 | Method for the synthesis of phospholipid ethers | CELLECTAR, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090018357-A1 | Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use | CELL ACQUISITION CORP. | 2009-01-15 | — | — | US | disclosed |
| US-20080312459-A1 | Method for the synthesis of phospholipid ethers | CELL ACQUISITION CORP. | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018357-A1 | Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use | PHOSPHO1, PEBP1, SGMS1 | NPC1 204/4885MAPT 4708/4885RAB9A 956/4885 |
| US-20080312459-A1 | Method for the synthesis of phospholipid ethers | PHOSPHO1, PLEC, PLA2G2C | NPC1 1515/4885MAPT 4208/4885RAB9A 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.